AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15504187 — intervention group
Group type: COMPARATOR
Intervention: Comparison between adjacent levels of sevoflurane (0 vs. 0.2 MAC)
Number of subjects: 9
Study 15504187 — intervention group
Group type: COMPARATOR
Intervention: Comparison between adjacent levels of sevoflurane (0.2 MAC vs. 0.4 MAC)
Number of subjects: 9
Study 15504187 — intervention group
Group type: COMPARATOR
Intervention: Comparison between adjacent levels of sevoflurane (0.4 MAC vs. 1 MAC)
Number of subjects: 9
Study 11050521 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia started before surgery (12 patients received epidural mepivacaine 20 mg mL(‐1) and morphine perioperatively)
Number of subjects: 26
Study 11050521 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia started after surgery (14 patients received an epidural bolus of bupivacaine 2.5 mg mL(‐1) and morphine after skin closure)
Number of subjects: 26
Study 11050521 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (bupivacaine 2.5 mg mL(‐1) with morphine administered for three postoperative days)
Number of subjects: 26
Study 11050521 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study 9493700 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg once daily)
Number of subjects: 59
Study 9493700 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (40 mg sustained-release twice daily)
Number of subjects: 59
Study 8112815 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine hydrochloride by Kopran Chem. Co.
Number of subjects: 0
Study 8112815 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine hydrochloride by Marrel Dow U.K. (Triludan)
Number of subjects: 0
Study 2906874 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin + beta-blocker
Number of subjects: 35
Study 2906874 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin + diuretic
Number of subjects: 35
Study 31157598 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination
Number of subjects: 624
Study 28284557 — intervention group
Group type: EXPERIMENTAL
Intervention: Binimetinib 45 mg orally twice daily
Number of subjects: 402
Study 28284557 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine 1000 mg/m2 intravenously every 3 weeks
Number of subjects: 402
Study 25719253 — intervention group
Group type: EXPERIMENTAL
Intervention: O3FA (omega-3 fatty acids)
Number of subjects: 496
Study 25719253 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 496
Study 23650092 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 60
Study 23650092 — intervention group
Group type: EXPERIMENTAL
Intervention: CPM plus active TENS
Number of subjects: 60
Study 23650092 — intervention group
Group type: COMPARATOR
Intervention: CPM plus placebo TENS
Number of subjects: 60
Study 23650092 — intervention group
Group type: EXPERIMENTAL
Intervention: CPM
Number of subjects: 60
Study 20975251 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-item Short Falls Efficacy Scale International (Short FES-I)
Number of subjects: 284
Study 20975251 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-item Falls Efficacy Scale (FES)
Number of subjects: 284
Study 20975251 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-item FES-I
Number of subjects: 284
Study 20975251 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-item Short FES-I
Number of subjects: 284
Study 18004988 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg tegaserod bid
Number of subjects: 30
Study 18004988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 20803855 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg of isobaric bupivacaine with 25 microg of fentanyl and 100 microg of morphine
Number of subjects: 80
Study 20803855 — intervention group
Group type: COMPARATOR
Intervention: 10 mg of isobaric bupivacaine with 25 microg of fentanyl and 100 microg of morphine
Number of subjects: 80
Study 16253158 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose perindopril (2 mg/d initially, increased to 2-4 mg/d)
Number of subjects: 66
Study 16253158 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose perindopril (2 mg/d initially, increased to 8-10 mg/d)
Number of subjects: 66
Study 16253158 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 healthy subjects)
Number of subjects: 66
Study 12140470 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vitamin K cream applied after laser treatment
Number of subjects: 22
Study 12140470 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle cream) applied after laser treatment
Number of subjects: 22
Study 12140470 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vitamin K cream applied before laser treatment
Number of subjects: 22
Study 12140470 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle cream) applied before laser treatment
Number of subjects: 22
Study 9874863 — intervention group
Group type: EXPERIMENTAL
Intervention: EACA (150 mg/kg, i.v. before CPB)
Number of subjects: 60
Study 9874863 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-EACA (PRP 10 ml/kg harvested with a plasma saver followed by i.v. EACA 150 mg/kg)
Number of subjects: 60
Study 9874863 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 7974602 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0
Study 7974602 — intervention group
Group type: COMPARATOR
Intervention: Aspirin and aggressive management of modifiable risk factors
Number of subjects: 0
Study 2658918 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral neomycin sulfate‐erythromycin base
Number of subjects: 54
Study 2658918 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ceftriaxone‐metronidazole preparation
Number of subjects: 54
Study 47638 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (4 mg i.v.)
Number of subjects: 6
Study 47638 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (100 mg p.o. daily)
Number of subjects: 6
Study 47638 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 6
Study 30885518 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily sunscreen use for 4.5 years
Number of subjects: 1621
Study 30885518 — intervention group
Group type: COMPARATOR
Intervention: Discretionary sunscreen use
Number of subjects: 1621
Study 30168349 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 0
Study 30168349 — intervention group
Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 0
Study 27578624 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication reconciliation and charting service
Number of subjects: 110
Study 27578624 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 110
Study 23702931 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg MK-4 daily
Number of subjects: 48
Study 23702931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 22552180 — intervention group
Group type: EXPERIMENTAL
Intervention: MiniArc
Number of subjects: 120
Study 22552180 — intervention group
Group type: COMPARATOR
Intervention: Ajust
Number of subjects: 120
Study 22552180 — intervention group
Group type: COMPARATOR
Intervention: TVT Secur System
Number of subjects: 120
Study 19712786 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited chiropractic care (8 weeks)
Number of subjects: 30
Study 19712786 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended chiropractic care (8 weeks + once per month for 10 months)
Number of subjects: 30
Study 19712786 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 30
Study 17261383 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a treatment for 24 months
Number of subjects: 102
Study 17261383 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 102
Study 17261383 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a treatment
Number of subjects: 102
Study 15167724 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A reconstituted with preserved saline
Number of subjects: 20
Study 15167724 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin type A reconstituted with nonpreserved saline
Number of subjects: 20
Study 11806433 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced ultrafiltration (BUF)
Number of subjects: 80
Study 11806433 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration (MUF)
Number of subjects: 80
Study 11806433 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced ultrafiltration with modified ultrafiltration (B+M)
Number of subjects: 80
Study 11806433 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 80
Study 9554266 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal OMV vaccine administered as nose drops or nasal spray
Number of subjects: 12
Study 9554266 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal OMV vaccine
Number of subjects: 12
Study 9554266 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal OMV vaccine with whole inactivated influenza virus
Number of subjects: 12
Study 7519191 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH)
Number of subjects: 27
Study 7519191 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study 2648723 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 0.5 g trice daily for 4 weeks
Number of subjects: 9
Study 31575640 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster‐CL
Number of subjects: 20
Study 31575640 — intervention group
Group type: COMPARATOR
Intervention: Standard‐CL
Number of subjects: 20
Study 29951098 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucket Handle Tympanoplasty
Number of subjects: 60
Study 29951098 — intervention group
Group type: COMPARATOR
Intervention: Cartilage Tympanoplasty
Number of subjects: 60
Study 27099151 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-unit cord blood transplantation
Number of subjects: 151
Study 27099151 — intervention group
Group type: COMPARATOR
Intervention: Single-unit cord blood transplantation
Number of subjects: 151
Study 27099151 — intervention group
Group type: COMPARATOR
Intervention: Busulfan, cyclophosphamide, and ATG
Number of subjects: 151
Study 25787877 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-g ginger supplementation
Number of subjects: 20
Study 25787877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24439186 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin (ALO, 25 mg, once daily) as monotherapy
Number of subjects: 491
Study 24439186 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin (ALO, 25 mg, once daily) as add-on to metformin
Number of subjects: 491
Study 24439186 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin (ALO, 25 mg, once daily) as add-on to pioglitazone ± metformin
Number of subjects: 491
Study 24439186 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) as monotherapy
Number of subjects: 491
Study 24439186 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) as add-on to metformin
Number of subjects: 491
Study 24439186 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) as add-on to pioglitazone ± metformin
Number of subjects: 491
Study 19624593 — intervention group
Group type: EXPERIMENTAL
Intervention: Butea superba (BS) 100 mg
Number of subjects: 32
Study 19624593 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil 50 mg
Number of subjects: 32
Study 18257943 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g cocoa powder dissolved in 250 ml whole milk (CC-M)
Number of subjects: 21
Study 18257943 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g cocoa powder dissolved in 250 ml water (CC-W)
Number of subjects: 21
Study 18257943 — intervention group
Group type: COMPARATOR
Intervention: 250 ml whole milk
Number of subjects: 21
Study 16634954 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional chlorhexidine solution (0.2%; CHX)
Number of subjects: 21
Study 16634954 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine solution with anti-discolouration system (0.2%, alcohol-free chlorhexidine solution (CSP))
Number of subjects: 21
Study 16634954 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution (Pla)
Number of subjects: 21
Study 12372669 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (10 to 40 mg/day) with possible addition of enalapril (5 to 20 mg/day) or hydrochlorothiazide (12.5 to 25 mg/day)
Number of subjects: 808
Study 12372669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 808
Study 10399796 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐hu‐Epo)
Number of subjects: 70
Study 10399796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 7754246 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac 0.1%
Number of subjects: 37
Study 7754246 — intervention group
Group type: COMPARATOR
Intervention: Topical betamethasone 0.1%
Number of subjects: 37
Study 2184557 — intervention group
Group type: EXPERIMENTAL
Intervention: Insuject-X
Number of subjects: 21
Study 2184557 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin (conventional treatment)
Number of subjects: 21
Study 363773 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of ascorbic acid
Number of subjects: 6
Study 363773 — intervention group
Group type: COMPARATOR
Intervention: Lactose capsules
Number of subjects: 6
Study 31748982 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon plasma treatment (PAT)
Number of subjects: 66
Study 31748982 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet irradiation (UV)
Number of subjects: 66
Study 31748982 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 66
Study 29699758 — intervention group
Group type: EXPERIMENTAL
Intervention: sildenafil 100 mg
Number of subjects: 279
Study 29699758 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 279
Study 26826044 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling (experimental group)
Number of subjects: 62
Study 26826044 — intervention group
Group type: COMPARATOR
Intervention: Standard outpatient clinic service (control group)
Number of subjects: 62
Study 24837141 — intervention group
Group type: EXPERIMENTAL
Intervention: TheraTogs strapping system and static ground reaction ankle foot orthoses (Group C)
Number of subjects: 57
Study 24837141 — intervention group
Group type: EXPERIMENTAL
Intervention: TheraTogs strapping system (Group B)
Number of subjects: 57
Study 24837141 — intervention group
Group type: COMPARATOR
Intervention: Traditional neuro-developmental physical therapy program without orthotic management (Group A)
Number of subjects: 57
Study 24331774 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal treatment with topical antibiotics
Number of subjects: 21
Study 24331774 — intervention group
Group type: COMPARATOR
Intervention: No periodontal treatment (control group)
Number of subjects: 21
Study 20585223 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Balance Childhood program (intervention group)
Number of subjects: 67
Study 20585223 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study 20585223 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study 19145994 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot fruit drink
Number of subjects: 30
Study 19145994 — intervention group
Group type: COMPARATOR
Intervention: Room temperature drink
Number of subjects: 30
Study 16377677 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole (200 mg four times a day or 400 mg twice a day)
Number of subjects: 24
Study 12823855 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) plus calcium and vitamin D3
Number of subjects: 88
Study 12823855 — intervention group
Group type: COMPARATOR
Intervention: Calcium and vitamin D3 alone
Number of subjects: 88
Study 10948785 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-managed diabetes care program
Number of subjects: 181
Study 10948785 — intervention group
Group type: COMPARATOR
Intervention: Control group (general clinic setting)
Number of subjects: 181
Study 9002009 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid Arthritis (RA)
Number of subjects: 600
Study 9002009 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoarthritis (OA)
Number of subjects: 600
Study 8292064 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine syrup (5 or 10 mg QD)
Number of subjects: 236
Study 8292064 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine suspension (30 mg b.i.d.)
Number of subjects: 236
Study 3492571 — intervention group
Group type: EXPERIMENTAL
Intervention: Various serological assays of antibody to PRP
Number of subjects: 0
Study 3492571 — intervention group
Group type: EXPERIMENTAL
Intervention: Different antigen preparations used in assays
Number of subjects: 0
Study 3492571 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardization on a single assay
Number of subjects: 0
Study 28375699 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotor-delivered screening and brief intervention (SBI)
Number of subjects: 32
Study 26829763 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve integrity monitor (NIM) group
Number of subjects: 0
Study 26829763 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 23642400 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support guided by repeated measurements of resting energy requirements (REE)
Number of subjects: 50
Study 23109641 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 12729
Study 23109641 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 12729
Study 20398481 — intervention group
Group type: EXPERIMENTAL
Intervention: EH + MS group
Number of subjects: 972
Study 20398481 — intervention group
Group type: COMPARATOR
Intervention: EH + non MS group
Number of subjects: 972
Study 20398481 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 972
Study 18760066 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Dose Infusion of low molecular weight iron dextran
Number of subjects: 100
Study 18760066 — intervention group
Group type: COMPARATOR
Intervention: Oral iron supplementation (ferrous sulphate 200 mg three times a day)
Number of subjects: 100
Study 15966343 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (88 min bout, 80% of 10-repetition maximum, 4 sets of 10 repetitions of 11 exercises)
Number of subjects: 11
Study 15966343 — intervention group
Group type: COMPARATOR
Intervention: Control (inactive)
Number of subjects: 11
Study 11957809 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 0
Study 11957809 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0
Study 11957809 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinantly produced TNF-α soluble receptor
Number of subjects: 0
Study 9540875 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate (1:1 mixture with Lipoidol)
Number of subjects: 50
Study 9540875 — intervention group
Group type: COMPARATOR
Intervention: Sodium tetradecyl sulphate (1.5%)
Number of subjects: 50
Study 8087526 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 0
Study 8087526 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic cranial irradiation (PCI)
Number of subjects: 0
Study 2574502 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpidem 50 mg
Number of subjects: 208
Study 2574502 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpidem 75 mg
Number of subjects: 208
Study 2574502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 4827071 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological testing in vitro of muscle biopsy specimens
Number of subjects: 0
Study 4827071 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 7192146 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 20
Study 7192146 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol retard 160 mg
Number of subjects: 20
Study 31506252 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacrospinous hysteropexy
Number of subjects: 204
Study 31506252 — intervention group
Group type: COMPARATOR
Intervention: Vaginal hysterectomy with uterosacral ligament suspension
Number of subjects: 204
Study 28940737 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MED)
Number of subjects: 106
Study 28940737 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (LF)
Number of subjects: 106
Study 28940737 — intervention group
Group type: COMPARATOR
Intervention: NonMetS-OB
Number of subjects: 106
Study 28940737 — intervention group
Group type: COMPARATOR
Intervention: NonMetS-NonOB
Number of subjects: 106
Study 26468683 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 40
Study 26468683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23689001 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask anesthesia with high-frequency low tidal volume lung ventilation
Number of subjects: 60
Study 23689001 — intervention group
Group type: COMPARATOR
Intervention: Intubation anesthesia with one-lung ventilation
Number of subjects: 60
Study 21459942 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation plus educational-behavioral program (n = 20)
Number of subjects: 62
Study 21459942 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational-behavioral program only (n = 20)
Number of subjects: 62
Study 21459942 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 22)
Number of subjects: 62
Study 19663523 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil (50, 100, 200, 250, 300 or 400 mg)
Number of subjects: 0
Study 19663523 — intervention group
Group type: COMPARATOR
Intervention: Modafinil (400 mg)
Number of subjects: 0
Study 17277001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate (oral or intravenous) at different doses and for variable time intervals
Number of subjects: 0